Biophytis: Trading Suspended on Euronext Growth, Resumption Expected After Late July 2026
Biophytis announced on Monday the temporary suspension of its shares on Euronext Growth Paris, following the failure to meet the publication schedule of its annual financial report for the fiscal year 2025. The waiting period before trading resumes will span several weeks.
Biophytis issued a statement at 11:00 PM CET on Monday announcing that the suspension of its shares on Euronext Growth Paris took effect the same day. The French biotech cited an operational delay in the preparation of its financial statements for the fiscal year ended December 31, 2025. The annual report could not be published on the initially scheduled date, a publication that is essential for the resumption of trading. The suspension took immediate effect. No trading could take place from this Monday onwards.
Annual Report Expected by End of July 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Biophytis indicates that the annual report will be published following the account certification by the auditors, which is expected to be completed by no later than the end of July 2026. The lifting of the trading suspension will directly depend on this publication. The company commits to communicate the exact date of resumption as soon as it is confirmed.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
